Combining stereotactic radiosurgery with an epidermal growth factor receptor-tyrosine kinase inhibitor may benefit patients with brain metastases from NSCLC but further study is needed to change standard of care.
New risk calculator aids clinicians in supporting patients with non-small cell lung cancer
New model demonstrates lifesaving capabilities of next-generation sequencing for patients with non-squamous non-small cell lung cancer
A new treatment option for patients with advanced non-small-cell lung cancer (NSCLC) harboring a KRASG12C mutation is on the horizon.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Preliminary results from the phase 3 ADAURA trial indicate that osimertinib is superior to placebo in adjuvant treatment of EGFR-mutated non-small cell lung cancer.
Single-fraction SBRT is safe and effective in treating early stage, medically inoperable NSCLC, according to a ten-year retrospective study of 229 patients, the largest single-institution report to date.
The selective RET inhibitor selpercatinib is safe and effective in both treated and treatment-naïve patients with RET fusion-positive NSCLC.
Outcomes correlate with the number of brain metastases primarily in patients without two actionable molecular targets: epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations.
A $4 million National Cancer Institute grant will help Cleveland Clinic mathematical oncologist Jacob Scott, MD, DPhil, study how ecological and evolutionary mechanisms contribute to lung cancer development, progression and drug resistance.
Two analyses of a large Cleveland Clinic cohort confirm the importance of immunotherapy in treating NSCLC brain metastases and reveal critical indicators of efficacy.